Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
Tharimmune在ACG 2024展示了關於TH104用於慢性肝病中中至重度瘙癢的1期數據；未觀察到阿片類藥物戒斷效應，支持2025年預期的2期結果的安全性。
Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
Tharimmune在ACG 2024展示了關於TH104用於慢性肝病中中至重度瘙癢的1期數據；未觀察到阿片類藥物戒斷效應，支持2025年預期的2期結果的安全性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間